BioSante second quarter net loss increases to $15.

Due to this concentrate on LibiGel advancement and the business’s planned carry out of the LibiGel plan, research and development expenditures increased to around $11.1 million and $26.june 30 0 million for the three and six month intervals ended, 2011 from $8.7 million and $18.june 30 1 million for the three and six month intervals ended, 2010.. BioSante second quarter net loss increases to $15.0 million BioSante Pharmaceuticals, Inc. today announced its monetary results for the next quarter of 2011. THE BUSINESS’S cash and money equivalents by June 30, 2011 had been around $37.1 million. BioSante incurred a net lack of around $15.0 million or per talk about for the one fourth ended June 30, 2011, in comparison to a net lack of $10.8 million or per talk about for the same period this year 2010.S..

BioSpecifics Systems’ XIAFLEX receives FDA approval BioSpecifics Systems Corp. , a biopharmaceutical company developing 1st in class collagenase-based items, announced that the U today.S. Dupuytren’s contracture is certainly a debilitating disease caused by extreme collagen deposition that triggers contractures of the fingertips. THE BUSINESS’S partner, Auxilium Pharmaceuticals Inc., expects to release XIAFLEX in past due March, 2010. We wish to acknowledge the attempts of the researchers and clinicians who’ve caused XIAFLEX over a long time to usher in a fresh era of expect an incredible number of patients that have problems with this condition, mentioned Thomas L.